Vendor, San Diego, CA
Cidara Therapeutics Inc.
UEI FKP3JZ9RUNY9, CAGE 7A5L2
1 award and $58,051,983 obligated between September 30, 2025 and June 2, 2026, 100% under full and open competition, against 1.0 offers on average where reported. 1 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $58,051,983 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $58,051,983 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Solicitations it won
SAM.gov opportunities whose award USAspending attributes to this vendor.
- Development of CD388 as a long-lasting prophylactic anti-viral option for protection against the health impacts caused by influenza
Office of Assistant Secretary for Preparedness and Response, Barda - Aspr / Daappo / Barda DCMA
Award noticeNAICS 541714San Diego, CA75A50125C00017Awarded to Cidara Therapeutics Inc. for $339,189,481
Posted Oct 14, 2025
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50125C00017Definitive Contract, September 30, 2025, Full and Open Competition, 1 offersSolicitation | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Development of CD388 as a Long-Lasting Prophylactic Anti-Viral Option for Protection Against the Health Impacts Caused by InfluenzaNAICS 541714, PSC AN14 | $58,051,983 |
- Places of performance
- California
- Product and service codes
- AN14 Health R&D Services; Health Care Services; R&D Administrative Expenses
- Transactions
- 2 across 1 awards